Relevant bibliographies by topics / Recombinant Salmonella vaccine

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Book chapters

Academic literature on the topic 'Recombinant Salmonella vaccine'

Author: Grafiati
Published: 4 June 2021
Last updated: 5 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Recombinant Salmonella vaccine.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Recombinant Salmonella vaccine"

1

Kraehenbuhl, J. P., I. Corthésy-Theulaz, and D. Nardelli-Haefliger. "Recombinant Salmonella as vaccine carriers." Research in Immunology 149, no. 1 (January 1998): 87–90. http://dx.doi.org/10.1016/s0923-2494(98)80054-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Bradley, Mark P., Lyn A. Hinds, and Peter H. Bird. "A bait-delivered immunocontraceptive vaccine for the European red fox (Vulpes vulpes) by the year 2002?" Reproduction, Fertility and Development 9, no. 1 (1997): 111. http://dx.doi.org/10.1071/r96066.

Full text
Abstract:
An orally-delivered immunocontraceptive vaccine is being developed for the control of fox populations. A number of genes (PH-20, LDH-C4, ZP3) encoding gamete proteins have been cloned, produced in recombinant expression systems and used in fertility trials to test the efficacy of these antigens. As the immunocontraceptive vaccine will be delivered in a bait, there is a requirement for a greater understanding of the immune responses of the reproductive mucosa in canids, and the assessment of the best vaccine delivery system that will evoke a mucosal antibody response. Several vaccine delivery systems including microencapsulated antigens, and both vaccinia virus and bacterial vectors are being investigated. Oral administration of Salmonella typhimurium recombinants expressing different fox sperm antigens stimulates both systemic IgG responses to the antigen and a mucosal immune response within the female reproductive tract in the fox, indicating that salmonella may have potential with respect to the oral delivery of antigen. The enhancement of mucosal immune responses to orally-delivered vaccines is also being examined, research focussing on the possible use of fox-specific cytokines or the β-subunit of cholera toxin in forming part of the vaccine construct.
APA, Harvard, Vancouver, ISO, and other styles
3

Husseiny, Mohamed I., and Michael Hensel. "Rapid Method for the Construction of Salmonella enterica Serovar Typhimurium Vaccine Carrier Strains." Infection and Immunity 73, no. 3 (March 2005): 1598–605. http://dx.doi.org/10.1128/iai.73.3.1598-1605.2005.

Full text
Abstract:
ABSTRACT Salmonella enterica serovar Typhimurium is a versatile organism for the generation of live recombinant vaccines for mucosal immunization. Various strategies have been devised for the stable and efficient expression of heterologous antigens by attenuated S. enterica strains, but these methods often require complex manipulations. Use of phage λ Red recombinase has recently been devised for gene replacements in Escherichia coli and S. enterica after introduction of PCR products. Based on this method, we have developed an approach that allows the integration of recombinant expression cassettes for heterologous antigens in a single step. The recombinant construct is integrated into the chromosome and is devoid of any selective marker such as antibiotic resistance. We observed the stable expression of model antigens without selective pressure. In addition, the method allows the simultaneous generation of attenuating mutations by gene deletions. The novel “knock-in” approach allows the rapid and efficient construction of recombinant Salmonella strains as vaccine carriers.
APA, Harvard, Vancouver, ISO, and other styles
4

Potera, Carol. "Phosphatase Makes Recombinant Salmonella Vaccine Vectors Safer." Microbe Magazine 6, no. 11 (January 1, 2011): 471–72. http://dx.doi.org/10.1128/microbe.6.471.1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Kang, Ho Young, Jay Srinivasan, and Roy Curtiss. "Immune Responses to Recombinant Pneumococcal PspA Antigen Delivered by Live Attenuated Salmonella enterica Serovar Typhimurium Vaccine." Infection and Immunity 70, no. 4 (April 2002): 1739–49. http://dx.doi.org/10.1128/iai.70.4.1739-1749.2002.

Full text
Abstract:
ABSTRACT Attenuated Salmonella enterica serovar Typhimurium expressing recombinant antigens from other pathogens elicits primarily a Th1-type dominant immune response to both recombinant and Salmonella antigens. The immunogenicity and appropriate subcellular location of the recombinant antigen in the Salmonella vaccine strain may contribute to augmenting immune responses by facilitating adequate exposure of recombinant antigen to antigen-presenting cells for processing. To allow for secretion from gram-negative bacteria and overexpression of antigen, a DNA fragment encoding a highly antigenic α-helical region of PspA (pneumococcal surface protein A) was subcloned downstream from the β-lactamase signal sequence in the multicopy Asd+ pYA3493 vector to create pYA3494. pYA3493 was derived from a class of Asd+ vectors with reduced expression of Asd to minimize selective disadvantage and enhance immunization of expressed recombinant antigens. The S. enterica serovar Typhimurium vaccine strain was constructed by the introduction of deletion mutations Δcrp-28 and ΔasdA16. Approximately 50% of the recombinant PspA (rPspA) expressed in a Salmonella strain harboring pYA3494 was detected in the combined supernatant and periplasmic fractions of broth-grown recombinant Salmonella. After a single oral immunization in BALB/c mice with 109 CFU of the recombinant Salmonella vaccine strain carrying pYA3494, immunoglobulin G (IgG) antibody responses were stimulated to both the heterologous antigen rPspA and Salmonella lipopolysaccharide (LPS) and outer membrane proteins (OMPs). About half, and even more at later times after immunization, of the antibodies induced to rPspA were IgG1 (indicating a Th2-type response), whereas 60 to 70% of the antibodies to LPS and 80 to 90% of those to OMPs were IgG2a (indicating a Th1-type response). A sublethal infection with Streptococcus pneumoniae WU2 boosted PspA antibody levels and maintained IgG2a/IgG1 ratios similar to those seen before the challenge. Oral immunization with Salmonella-PspA vaccine protected 60% of immunized mice from death after intraperitoneal challenge with 50 times the 50% lethal dose of virulent S. pneumoniae WU2.
APA, Harvard, Vancouver, ISO, and other styles
6

Su, Huali, Qing Liu, Xiaoping Bian, Shifeng Wang, Roy Curtiss, and Qingke Kong. "Synthesis and delivery of Streptococcus pneumoniae capsular polysaccharides by recombinant attenuated Salmonella vaccines." Proceedings of the National Academy of Sciences 118, no. 2 (December 30, 2020): e2013350118. http://dx.doi.org/10.1073/pnas.2013350118.

Full text
Abstract:
Streptococcus pneumoniae capsular polysaccharides (CPSs) are major determinants of bacterial pathogenicity. CPSs of different serotypes form the main components of the pneumococcal vaccines Pneumovax, Prevnar7, and Prevnar13, which substantially reduced the S. pneumoniae disease burden in developed countries. However, the laborious production processes of traditional polysaccharide-based vaccines have raised the cost of the vaccines and limited their impact in developing countries. The aim of this study is to develop a kind of low-cost live vaccine based on using the recombinant attenuated Salmonella vaccine (RASV) system to protect against pneumococcal infections. We cloned genes for seven different serotypes of CPSs to be expressed by the RASV strain. Oral immunization of mice with the RASV-CPS strains elicited robust Th1 biased adaptive immune responses. All the CPS-specific antisera mediated opsonophagocytic killing of the corresponding serotype of S. pneumoniae in vitro. The RASV-CPS2 and RASV-CPS3 strains provided efficient protection of mice against challenge infections with either S. pneumoniae strain D39 or WU2. Synthesis and delivery of S. pneumoniae CPSs using the RASV strains provide an innovative strategy for low-cost pneumococcal vaccine development, production, and use.
APA, Harvard, Vancouver, ISO, and other styles
7

Gunn, Bronwyn M., Soo-Young Wanda, Dana Burshell, Caihong Wang, and Roy Curtiss. "Construction of Recombinant Attenuated Salmonella enterica Serovar Typhimurium Vaccine Vector Strains for Safety in Newborn and Infant Mice." Clinical and Vaccine Immunology 17, no. 3 (March 2010): 354–62. http://dx.doi.org/10.1128/cvi.00412-09.

Full text
Abstract:
ABSTRACT Recombinant bacterial vaccines must be safe, efficacious, and well tolerated, especially when administered to newborns and infants to prevent diseases of early childhood. Many means of attenuation have been shown to render vaccine strains susceptible to host defenses or unable to colonize lymphoid tissue effectively, thus decreasing their immunogenicity. We have constructed recombinant attenuated Salmonella vaccine strains that display high levels of attenuation while retaining the ability to induce high levels of immunogenicity and are well tolerated in high doses when administered to infant mice as young as 24 h old. The strains contain three means of regulated delayed attenuation, as well as a constellation of additional mutations that aid in enhancing safety, regulate antigen expression, and reduce disease symptoms commonly associated with Salmonella infection. The vaccine strains are well tolerated when orally administered to infant mice 24 h old at doses as high as 3.5 × 108 CFU.
APA, Harvard, Vancouver, ISO, and other styles
8

Cao, Y., Z. Wen, and D. Lu. "Construction of a recombinant oral vaccine against Salmonella typhi and Salmonella typhimurium." Infection and Immunity 60, no. 7 (1992): 2823–27. http://dx.doi.org/10.1128/iai.60.7.2823-2827.1992.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Curtiss III, Roy, Wei Xin, Yuhua Li, Wei Kong, Soo-Young Wanda, Bronwyn Gunn, and Shifeng Wang. "New Technologies in Using Recombinant Attenuated Salmonella Vaccine Vectors." Critical Reviews™ in Immunology 30, no. 3 (2010): 255–70. http://dx.doi.org/10.1615/critrevimmunol.v30.i3.30.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Wang, Shifeng, Qingke Kong, and Roy Curtiss. "New technologies in developing recombinant attenuated Salmonella vaccine vectors." Microbial Pathogenesis 58 (May 2013): 17–28. http://dx.doi.org/10.1016/j.micpath.2012.10.006.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Recombinant Salmonella vaccine"

1

Hand, Nicholas. "Development of a Recombinant Attenuated Salmonella Cancer Vaccine." Thesis, The George Washington University, 2017. http://pqdtopen.proquest.com/#viewpdf?dispub=10635177.

Full text
Abstract:
<p>New treatments for neuroblastoma are desperately needed; high-risk neuroblastoma patients have a less than 50% five-year survival rate despite intensive treatment. The greatest impact on improving survival rates for cancer patients in recent years is the result of a number of immunotherapeutic approaches. A proportion of high-risk neuroblastoma patients undergo spontaneous regression, possibly mediated by the immune system, indicating the potential of immunotherapies targeting neuroblastoma-associated antigens. Recombinant attenuated Salmonella vaccines (RASV) are cost-effective and have shown efficacy against a number of pathogen-associated antigens and are easily adapted for use as cancer immunotherapies. Here we cloned survivin, a neuroblastoma tumor-associated antigen into RASV expression plasmids to develop 24 RASV candidate vaccines with an array of select phenotypes. While conventional recombinant attenuated Salmonella vaccines are permanently attenuated, the RASV used here are engineered with inducible in vivo attenuation and other delayed phenotypes shown to improve immune responses. Survivin expression did not impact the growth or stability of any of the RASV constructs. Six of the constructs were tested in vivo, the RASV survived in the gut lumen, and all RASV-immunized mice produced anti-Salmonella responses. Protein/adjuvant immunized mice produced humoral and cellular survivin specific immune responses; however two independent in vivo experiments showed that no survivin specific immune responses were induced in survivin-expressing RASV immunized mice. Based on the results, a number of improvements to the future development of the vaccine are suggested.
APA, Harvard, Vancouver, ISO, and other styles
2

Breau, Cathy. "Development of an oral recombinant chancroid vaccine delivered by attenuated Salmonella typhimurium SL3261." Thesis, University of Ottawa (Canada), 2009. http://hdl.handle.net/10393/28079.

Full text
Abstract:
Chancroid, a sexually transmitted genital ulcer disease caused by the Gram-negative bacterium Haemophilus ducreyi, facilitates the acquisition and transmission of H1V. An effective vaccine against chancroid has yet to be developed. We hypothesize that a Salmonella vector-based vaccine, expressing H. ducreyi antigens, could confer protective immunity in the rabbit model of H. ducreyi infection. The H. ducreyi outer membrane hemoglobin receptor HgbA has been shown to be a suitable vaccine candidate. HgbA was expressed from S. typhimurium SL3261 (pnirBhgbA) but not from the control strain, S. typhimurium SL3261 (pnirB). After a single dose or three doses, at two-week intervals of the vaccine, no antibody response to HgbA was detected in the rabbit model. The vaccine administered was immunogenic and survived in vivo passage. In this small animal trial, we were unable to induce protective immunity against chancroid. We conclude that the vaccine does not confer protective immunity against chancroid.
APA, Harvard, Vancouver, ISO, and other styles
3

O’Meara, Kellie Marcella. "Evaluation of Recombinant Salmonella Expressing CD154 for Enhanced Immune Responses in Commercial Turkeys." The Ohio State University, 2009. http://rave.ohiolink.edu/etdc/view?acc_num=osu1246567532.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Kremer, Courtney J. "Evaluation of Recombinant Salmonella Expressing the Flagellar Protein FliC for Enhanced Immune Responses in Commercial Turkeys." The Ohio State University, 2009. http://rave.ohiolink.edu/etdc/view?acc_num=osu1246568225.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Silva, Maria Elizabeth. "Development of a Recombinant Attenuated Salmonella Vaccine System for Taenia Solium Cysticercosis in Pigs." Digital Archive @ GSU, 2010. http://digitalarchive.gsu.edu/biology_diss/81.

Full text
Abstract:
Taenia solium is a cestode that has a two-hosts life cycle. The adult tapeworm causes an asymptomatic disease known as taeniasis whereas the larval stage causes a disease called cysticercosis. In humans, the most common localization for the larvae is the central nervous system where it produces the neurological disorder neurocysticerco-sis. Previous works by several research groups around the world have shown that T. so-lium is a potentially eradicable parasite. Control programs have included treatment of human and pig populations with antihelmintics in conjunction with health education and are now considering vaccination of naïve piglets. The potential of a live vector vaccine system to deliver Taenia solium Tsol18, a proven protective antigen, to prevent transmission of cysticercosis was investigated. An attenuated strain of Salmonella enterica serovar Typhimurium χ9402 was used to develop an oral delivery system. Tsol18 gene was cloned downstream from the β-lactamase signal sequence in a multicopy asd + plasmid vector pYA3620 to yield plasmid pYA3620/Tsol18 and then transformed into the vaccine strain. The recombinant atte-nuated salmonella vaccine construct was stable for 50 generations and expressed rTsol18. Immunization of mice either with one or two doses of 109 CFU of the recombi-nant vaccine strain carrying plasmid pYA3620/Tsol18 elicited specific antibody response to Salmonella self antigens and to rTsol18. Moreover, oral immunization of piglets with 1012 CFU of the vaccine construction significantly reduced the numbers of viable cysts after challenged. The development of a quantitative assay to detect specific antibodies against Tsol18 is also presented here. The Falcon assay screening test –enzyme linked immu-noabsorbant assay (FAST-ELISA) format was used to develop a quantitative antibody detection assay. We have cloned, expressed and purified rTsol18. With purified porcine IgGs we constructed a standard curve that can be used to quantify the immune re-sponse. Our Fast-ELISA was able to follow the kinetics of the immune response in vac-cinated pigs from an experimental trial. The data we present here provides the basis for a safe, affordable and easy vaccine delivery system that can be used as an adjunct in control programs.
APA, Harvard, Vancouver, ISO, and other styles
6

Łaniewski, Paweł, Chang-Ho Baek, Kenneth L. Roland, and Roy Curtiss. "Analysis of Spleen-Induced Fimbria Production in Recombinant Attenuated Salmonella enterica Serovar Typhimurium Vaccine Strains." AMER SOC MICROBIOLOGY, 2017. http://hdl.handle.net/10150/625743.

Full text
Abstract:
Salmonella enterica serovar Typhimurium genome encodes 13 fimbrial operons. Most of the fimbriae encoded by these operons are not produced under laboratory conditions but are likely to be synthesized in vivo. We used an in vivo expression technology (IVET) strategy to identify four fimbrial operons, agf, saf, sti, and stc that are expressed in the spleen. When any three of these operons were deleted, the strain retained wild-type virulence. However, when all four operons were deleted, the resulting strain was completely attenuated, indicating that these four fimbriae play functionally redundant roles critical for virulence. In mice, oral doses of as low as 1 x 10(5) CFU of the strain with four fimbrial operons deleted provided 100% protection against challenge with 1 x 10(9) CFU of wild-type S. Typhimurium. We also examined the possible effect of these fimbriae on the ability of a Salmonella vaccine strain to deliver a guest antigen. We modified one of our established attenuated vaccine strains, chi 9088, to delete three fimbrial operons while the fourth operon was constitutively expressed. Each derivative was modified to express the Streptococcus pneumoniae antigen PspA. Strains that constitutively expressed saf or stc elicited a strong Th1 response with significantly greater levels of anti-PspA serum IgG and greater protective efficacy than strains carrying saf or stc deletions. The isogenic strain in which all four operons were deleted generated the lowest anti-PspA levels and did not protect against challenge with virulent S. pneumoniae. Our results indicate that these fimbriae play important roles, as yet not understood, in Salmonella virulence and immunogenicity. IMPORTANCE Salmonella enterica is the leading cause of bacterial food-borne infection in the United States. S. Typhimurium is capable of producing up to 13 distinct surface structures called fimbriae that presumably mediate its adherence to surfaces. The roles of most of these fimbriae in disease are unknown. Identifying fimbriae produced during infection will provide important insights into how these bacterial structures contribute to disease and potentially induce protective immunity to Salmonella infection. We identified four fimbriae that are produced during infection. Deletion of all four of these fimbriae results in a significant reduction in virulence. We explored ways in which the expression of these fimbriae may be exploited for use in recombinant Salmonella vaccine strains and found that production of Saf and Stc fimbriae are important for generating a strong immune response against a vectored antigen. This work provides new insight into the role of fimbriae in disease and their potential for improving the efficacy of Salmonella-based vaccines.
APA, Harvard, Vancouver, ISO, and other styles
7

Holden, James Anthony, and jamesholden@netspace net au. "Vaccination Strategies for the Prevention of Swine Dysentery." RMIT University. Applied Sciences, 2006. http://adt.lib.rmit.edu.au/adt/public/adt-VIT20070112.122102.

Full text
Abstract:
The SmpA outer membrane lipoprotein of B. hyodysenteriae has several characteristics that indicate the potential to protect against swine dysentery (SD). It localises to the outer membrane and antibodies directed against SmpA can prevent the growth of B. hyodysenteriae in vitro. There is some variation observed in the distribution and expression of the SmpA lipoprotein, suggesting that vaccination with SmpA may not provide protection against challenge with a heterologous B. hyodysenteriae strain. This study has characterised the variation at the smpA locus, and in the process has identified a novel gene, smpB. There is very low similarity between smpB and smpA, with the exception of an identical lipoprotein signal sequence. This suggests that SmpB may be translocated to the outer membrane of B. hyodysenteriae in a similar fashion to SmpA. The results described in this thesis indicate that strains of B. hyodysenteriae harbour either smpA or smpB, but not both, explaining the earlier results of Turner et al. (1991). The presumed outer membrane location of SmpB lead to further investigations into its potential to protect mice from infection with B. hyodysenteriae. Swine Dysentery is a inflammatory disease of the swine colon. Therefore it is believed that a mucosal immune response may provide increased protection against challenge. In this study, vaccination of mice with recombinant SmpB elicited high levels of serum antibodies, induced the production of Interleukin-4 producing T lymphocytes and decreased the observed histological effects after challenge with virulent B. hyodysenteriae. In efforts to increase the protected conferred by vaccination with SmpB, recombinant Salmonella typhimurium STM-1 vaccines were created to express SmpB or deliver DNA vaccines encoding SmpB. Vaccination with these recombinant Salmonella vectors did not induce a measurable SmpB specific immune response. Macrophage survival and plasmid stability studies indicated that this was due to instability of the expression plasmids in STM-1. Although SmpB will only ever protect against strains of B. hyodysenteriae harbouring smpB, these results indicate that with further research, SmpB (and SmpA) may contribute to protection from SD. Toxin production is an important aspect of the pathogenesis of many pathogenic bacteria. Vaccination with attenuated toxins is commonly used to prevent disease. In this study, the B. hyodysenteriae â-haemolysin HlyA was used to vaccinate mice to determine the protection induced after challenge. Vaccination of mice with recombinant HlyA induced significant levels of serum antibodies and lowered the observed pathological effects after challenge of vaccinated mice with virulent B. hyodysenteriae. In an attempt to increase the mucosal immune response and therefore the protection afforded after vaccination with HlyA, recombinant S. typhimurium STM-1 strains were created to express HlyA or deliver DNA vaccines encoding HlyA. Similar to the recombinant STM-1 vaccines expressing SmpB, a HlyA specific immune response was not observed by ELISA or ELISPOT analysis. Plasmid stability trials revealed that the inability to induce a detectable HlyA specific immune response by recombinant STM-1 vaccination may be due to ins tability of the plasmids. Outer membrane proteins are often important components of vaccines against bacterial and viral pathogens. Considering the variation observed in the smpA locus in this study resulting in the identification of smpB, further investigation into the distribution and conservation of outer membrane encoding genes in B. hyodysenteriae strains was undertaken. In particular, the blpAEFG, vspABCD and vspEFGH clusters were analysed for their distribution. It was demonstrated that genes that are B. hyodysenteriae specific (vspABCD and vspEFGH) displayed higher levels of polymorphism than those that are distributed amongst non-pathogenic species, such as B. innocens (which contains blpAEFG). This suggests that the variation in the vspABCD and vspEFGH clusters amongst B. hyodysenteriae strains may be a result of the exposure to the host immune system. Further investigation was undertaken by PFGE analysis and 2D-gel electrophoresis, to analyse genomic and proteomic variation at a global level. Although strains of B. hyodyse nteriae produced several different electrophoretic types (ET) upon PFGE analysis, only limited correlation between the PFGE ET, the polymorphisms in vspABCD and vspEFGH and the presence of smpA/smpB were observed. 2D-gel electrophoresis analysis of outer membrane preparations of two B. hyodysenteriae strain revealed several distinct differences in the outer membrane between B. hyodysenteriae strains. The observed differences in the proteins contained in the outer membrane of B. hyodysenteriae is important for vaccine design, as the induction of cross protection between strains of B. hyodysenteriae is essential for a effective vaccine.
APA, Harvard, Vancouver, ISO, and other styles
8

Sevil, Victoria. "Influence of oral boost immunizations with recombinant Salmonella vaccine strains on the antigen-specific CD8 T-cell induction." Diss., lmu, 2007. http://nbn-resolving.de/urn:nbn:de:bvb:19-72867.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Franzin, Fernanda Maria 1981. "Construção e analise da imunogenicidade de uma linhagem atenuada de Salmonella enterica produtora do dominio M2 do antigeno MAEBL de Plasmodium yoelii." [s.n.], 2009. http://repositorio.unicamp.br/jspui/handle/REPOSIP/317036.

Full text
Abstract:
Orientadores: Marcelo Brocchi, Fabio Trindade Maranhão Costa<br>Dissertação (mestrado) - Universidade Estadual de Campinas, Instituto de Biologia<br>Made available in DSpace on 2018-08-14T03:58:59Z (GMT). No. of bitstreams: 1 Franzin_FernandaMaria_M.pdf: 1412458 bytes, checksum: 2fe89ebc9e03c37ffcc48000024a232d (MD5) Previous issue date: 2009<br>Resumo: A malária é uma doença tropical causada pelo parasita Plasmodium spp e é considerada um sério problema de saúde pública. São aproximadamente 500 milhões de casos anuais e mais de um milhão de mortes, especialmente na África e Ásia. No Brasil, são 500 mil novos casos por ano, principalmente na região Amazônica. Esses elevados índices de mortalidade e morbidade são motivadores da busca por estratégias de controle e eliminação dessa doença. A vacinação é uma ferramenta promissora no controle e prevenção da malária, entretanto, uma vacina segura e efetiva ainda não está disponível, em parte devido ao complexo ciclo de vida do parasita e a expressão de diferentes antígenos em cada fase. O antígeno de membrana similar ao ligante de eritrócitos (MAEBL), é um forte candidato a ser usado no desenvolvimento de uma vacina efetiva contra a malária, uma vez que esse antígeno é expresso em diferentes períodos do ciclo de vida do parasita. Neste estudo, o domínio M2 do antígeno MAEBL de Plasmodium yoelli foi expresso em linhagens vivas atenuadas de Salmonella enterica Typhimurium (?3987, ?4550 e H683) e o uso dessas bactérias como vacina recombinante potencialmente indutora de proteção contra malária murina foi avaliado. Essas linhagens foram obtidas após construção e transdução do plasmídio pYA3137trc contendo a região m2 do gene maebl e a expressão do antígeno foi confirmada por immunoblotting. A administração oral das linhagens recombinantes a camundongos BALB/c/AnUnib resultou na colonização dos tecidos hospedeiros apenas pela linhagem H683. Essa linhagem foi então avaliada em termos de indução de resposta imune humoral contra M2 e capacidade de imunização no modelo murino. Apesar da resposta humoral contra M2 ter sido detectada in vivo, a linhagem recombinante não demonstrou proteção potencial contra a infecção por Plasmodium yoelii no modelo murino.<br>Abstract: Malaria is a tropical disease caused by the parasite Plasmodium spp and is considered a serious public health problem. There are about 500 million annual cases and more than one million of deaths, especially in Africa and Asia. In Brazil, there are 500.000 new cases per year, mainly in the Amazon region. Those high rates mortality motivate the search for strategies of control and elimination of this illness. The vaccination is a promising tool in the control and prevention of malaria; however, a safe and effective vaccine is not available yet, in part due to the complex life cycle of the parasite and expression of different antigens in each phase. Membrane antigen erythrocyte binding like (MAEBL) is a strong candidate to be used in the development of an effective vaccine against malaria, since this antigen is expressed in different periods of the parasite life cycle. In this work, the M2 domain of Plasmodium yoelli MAEBL antigen was expressed in attenuated strains of Salmonella enterica Typhimurium (?3987, ?4550 e H683) and the use of these bacterias as potential inductor of protection against murine malaria was evaluated. These strains were obtained by construction and transduction of the plasmid pYA3137trc carrying the m2 region of the maebl gene and the antigen expression was confirmed by immunoblotting. The oral administration of the recombinant strains to BALB/c/AnUnib mice resulted in the colonization of host tissues only for the H683 strain. This strain was further evaluated in terms of induction of humoral immune response against M2 and immunization capacity in murine model. Even though humoral response against M2 was detected in vivo, the recombinant strains did not shown protective potential against the infection of Plasmodium yoelii in murine model.<br>Mestrado<br>Genetica de Microorganismos<br>Mestre em Genética e Biologia Molecular
APA, Harvard, Vancouver, ISO, and other styles
10

Chin'ombe, Nyasha. "Recombinant Salmonella enterica serovar Typhimurium vaccine vector expressing green fluorescent protein as a model antigen or human immunodeficiency virus type 1 subtype C Gag." Doctoral thesis, University of Cape Town, 2007. http://hdl.handle.net/11427/2723.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Recombinant Salmonella vaccine"

1

Curtiss, Roy, Sandra M. Kelly, Paul A. Gulig, and Koji Nakayama. "Stable Recombinant Avirulent Salmonella Vaccine Strains." In Immunobiology of Proteins and Peptides V, 33–47. Boston, MA: Springer US, 1989. http://dx.doi.org/10.1007/978-1-4757-2046-4_4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Doggett, Teresa A., and Roy Curtiss. "Delivery of Antigens by Recombinant a Virulent Salmonella Strains." In Genetically Engineered Vaccines, 165–73. Boston, MA: Springer US, 1992. http://dx.doi.org/10.1007/978-1-4615-3410-5_18.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Rachmawati, Hidajah, Raditya Weka Nugraheni, and Firasti A.N. Sumadi. "In-Silico Approach in the Development of Salmonella Epitope Vaccine." In Salmonella - a Challenge From Farm to Fork [Working Title]. IntechOpen, 2021. http://dx.doi.org/10.5772/intechopen.96313.

Full text
Abstract:
In the case of infection control, one of our primary concerns is typhoid fever. According to WHO, typhoid prevalence in Indonesia is highly endemic. There is also the problem with the low efficacy of the available vaccine to prevent the disease. Therefore, there is an urgent need to develop a highly effective typhoid vaccine. One of the phases in vaccine development is an exploratory phase, a research-intensive phase of the vaccine development process designed to identify natural or synthetic antigens that might help prevent or treat a disease through computer in silico prediction targets. The vaccines developed through epitope peptide are designed to be safer, more efficacious, and less expensive than traditional vaccines. A thorough understanding of the disease agent, particularly critical epitopes to induce the appropriate immunological reaction, is required to achieve these aims. Mapping epitope sequences or antigenic peptides from pathogenic proteins recognized by B cells and T cells is crucial for vaccine development. Once the epitopes were identified, the polypeptide production could be produced through protein recombinant technology. The polypeptide vaccine, in the end, could be delivered using a liposomal delivery system.
APA, Harvard, Vancouver, ISO, and other styles
4

Curtiss, R., S. B. Porter, M. Munson, S. A. Tinge, J. O. Hassan, C. Gentry-Weeks, and S. M. Kelly. "NONRECOMBINANT AND RECOMBINANT AVIRULENT SALMONELLA LIVE VACCINES FOR POULTRY." In Colonization Control of Human Bacterial Enteropathologens in Poultry, 169–98. Elsevier, 1991. http://dx.doi.org/10.1016/b978-0-12-104280-6.50026-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Recombinant Salmonella vaccine' for particular source types:
Journal articles Dissertations / Theses
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography